Are NATR insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies NATR leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Stock Ratings / Health Care / NATR / insiders

PYXS (27) SIGA (68) KROS (64) KRRO (40) ⌘ Pro Terminal →

Nature's Sunshine Products Inc. (NATR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$12.25 -0.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $12.22

Nature's Sunshine Products Inc. (NATR) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $215.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NATR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NATR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Nature's Sunshine Products Inc. (NASDAQ: NATR) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $12.25 (-0.24% 1D, market cap $215.5M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 18/20. Across 1015 tracked Health Care issuers, NATR ranks #131 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NATR compare to PYXS and SIGA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NATR carries a Roarable C (64/100 RQD), trailing P/E of 11.1x, gross margin of 72.4%, and ROIC of 28.9%. By comparison, PYXS (Pyxis Oncology Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $216.4M) and SIGA (SIGA Technologies Inc.) posts a C+ grade (68/100 RQD, P/E 9.8x, ROIC 42.7%, cap $218.4M). Among the 5-stock peer group, SIGA leads on earnings multiple (9.8x) while KROS leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NATR?

▼

Per NATR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000275053), Nature's Sunshine Products Inc. generated $480.1M in revenue (+5.7% YoY), $19.5M in net income, and $28.8M in free cash flow against $261.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (72.4% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $12.22 (-0.23%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NATR)Realized 20D OHLCV Swing Band: ±6.1%

Deterministic 5-Pillar Attribution (64/100 Composite)

🔍 WHY NATR SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (28% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 6% FCF Margin ($28.8M FCF) & 72.4% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$12.76-0.4% Next Q

Q2 (-2Q)

Grade B-$12.71-2.5% Next Q

Q3 (-1Q)

Grade B-$12.39-1.1% Next Q

Current

Grade C$12.25+1.1% Hist 90D α

Trajectory: B (72) → C (64)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NATR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, NATR faces multiple-compression risk if 11.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 69.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($13.00) or 200D SMA ($20.44) invalidates the momentum regime and cuts Target Base ($12.58) toward Bear Floor ($9.81).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NATR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NATR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 64%NO 36%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

NATR Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (NATR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on NATR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (NATR Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NATR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.94%▲ RESISTANCE BREAKOUT

2026-11-03O $12.28H $12.28L $12.25C $12.25VOL 99.4K

RES: $10.92SUP: $11.34SMA50: $13.00SMA200: $20.44

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NATR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NATR Butterfly Map → + Track NATR →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

0.9%/yr Implied 5Y Growth

vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NATR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NATR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NATR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NATR)

Health Care Rank #131 of 1015 ⚔️ PYXS vs NATR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NATR vs. PYXS, SIGA, KROS, KRRO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nature's Sunshine Products Inc. (NATR) ranks #131 by composite RQD confidence (64/100, grade C) and #564 by equity capitalization ($215.5M). Within this direct 5-issuer industry benchmark cohort, SIGA leads on earnings valuation at 9.8x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. SIGA currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with NATR at 64/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NATR ACTIVE Nature's Sunshine Products Inc.	C	64/100	11.1x	72.4%	28.9%	-0.24%	$215.5M	Benchmark Subject
PYXS Pyxis Oncology Inc.	E	27/100	—	82.8%	-35.0%	-4.23%	$216.4M	/pyxs-vs-natr →
SIGA SIGA Technologies Inc.	C+	68/100	9.8x	68.6%	42.7%	-4.40%	$218.4M	/siga-vs-natr →
KROS Keros Therapeutics Inc.	C	64/100	—	—	85.0%	-2.82%	$218.9M	/kros-vs-natr →
KRRO Korro Bio Inc.	D-	40/100	—	—	-35.0%	+0.81%	$210.8M	/krro-vs-natr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000275053 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nature's Sunshine Products Inc. (NATR) reported GAAP revenue of $480.1M (+5.7% vs. FY2024 revenue of $454.4M , and +7.8% cumulative change since FY2023) , GAAP net income of $19.5M, operating cash flow of $35.3M, and free cash flow of $28.8M (+101.3% YoY). On the balance sheet, NATR closed FY2025 with $261.1M in total assets against $0 in total debt (Altman Z-Score: 4.33, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$480.1M	$19.5M	$35.3M	$28.8M	$261.1M	—
FY2024 (FY)	2024-12-31	$454.4M	$7.7M	$25.3M	$14.3M	$240.9M	—
FY2023 (FY)	2023-12-31	$445.3M	$15.1M	$41.2M	$41.2M	—	—

3. NATR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NATR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NATR compare to PYXS and SIGA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NATR?

Where is NATR trading relative to its 50-day, 200-day, and 52-week technical levels?

NATR last traded at $12.25 (-0.24% on volume of 99,356 shares), positioning the stock -5.77% below its 50-day simple moving average ($13.00) and -40.07% below its 200-day simple moving average ($20.44). Across its 52-week range of $12.00 to $28.14, NATR sits at the 1.5% percentile with a 14-day RSI of 38.2 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($11.50 to $13.00).

Direct Sub-Reports: NATR RQD Cockpit NATR 12M Forecast NATR Earnings & Move NATR Dividends & DRIP NATR Insiders & 13F NATR Whale Options NATR Profit Sankey NATR News & Why

ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ SEC XBRL & RQD VERIFIED

NATR — Nature's Sunshine Products Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nature's Sunshine Products Inc. (NATR) earns a live Roarable RQD composite score of 64/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $12.25 (-0.24% 1D, market capitalization $215.5M).

Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 28.9%, gross margin of 72.4%, operating margin of 5.2%, and free cash flow yield of 13.35%.
Whale 13F & Options Flow (4/20) + Insider Conviction (18/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 4.33, Piotroski F-Score of 8/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Nature's Sunshine Products Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). Market capitalization is reported as $0.2B (per the company profile). Gross margin is 72.4% (per market data), indicating the reported business carries a high gross margin profile.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nature's Sunshine Products Inc. (NATR) reported $480.1M in annual revenue (up from $454.4M in FY2024, +5.7% YoY) and $19.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($445.3M revenue, $15.1M net income) through FY2025, NATR scaled operating cash flow to $35.3M and free cash flow to $28.8M, backed by $261.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C • RQD 64/100): Strong cash generator (72.4% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $12.00 – $28.14 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 11.1x trailing P/E and 4.0x EV/EBITDA against 5.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), NATR carries a macro regime beta of 1.00 and gross margin of 72.4%.

Key Question #1: Can NATR sustain or expand its 5.2% operating margin and 28.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $480.1M and free cash flow of $28.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is NATR's 10.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NATR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nature's Sunshine Products Inc. (NATR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NATR Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

3 Reasons to avoid NATR and 1 stock to buy instead

Yahoo Finance report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Nature's Sunshine Products, Inc. Estimates – NASDAQ:NATR

TradingView report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Nature’s Sunshine Sets Third Quarter 2026 Conference Call for Wednesday, November 4, 2026, at 5:00 p.m. ET

Yahoo Finance report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Nature's Sunshine Products (NATR) Edges Higher as Shares Hold Above $12.50 - Conversion Trade

https://www.siam.in/ report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stock Traders Daily • 1d ago

(NATR) Risk Channels and Responsive Allocation

Stock Traders Daily report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingKey • 1d ago

Top U.S. Stock Gainers: Biggest Price Increases

TradingKey report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Nature's Sunshine Products (NATR) Edges Higher to $12.71 as Buyers Hold the Line Above Support - Continuation Pattern Picks

https://www.siam.in/ report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Most Active Stocks Today: U.S. Market

TradingKey report covering Nature's Sunshine Products Inc. (NATR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NATR Bull vs. Bear Conversation Board — What's Your Call at $12.25?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NATR 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $15.44 (+26.0%)

📌 Pinned Debate

Cash-generation metrics (ROIC 28.9%, FCF yield 13.35%) and a low P/E of 11.1 combine with a strong forensic balance sheet (Altman Z 4.3

Long NATR at $12.25 targeting $15.44. Cash-generation metrics (ROIC 28.9%, FCF yield 13.35%) and a low P/E of 11.1 combine with a strong forensic balance sheet (Altman Z 4.33, Piotroski F 8/9).. Institutional whale score is 4/20 and the risk/reward vs. the $12.00 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

@RedlineAuditor Shorting a 4/20 institutional whale-flow stock at $12.25 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $10.29 (-16.0%)

Spot @ $12.25

Thin operating margin of 5.2%, weak whale 13F flow (6/20), and a conditional 'Watch for Breakout' verdict leave the rating short of a b

Sitting on the sidelines or leaning short NATR above $12.25. Thin operating margin of 5.2%, weak whale 13F flow (6/20), and a conditional 'Watch for Breakout' verdict leave the rating short of a buy signal.. Until Fundamental Cash Engine (16/20) and FCF yield (13.35%) inflect higher, upside is capped near $28.14.